Report Categories
View AllRecent Articles
View All
UK Government Cracks Down on Driving Test Bot Resellers Potentially Disrupting a Lucrative Black Market
Waymo Recalls Thousands of Robotaxis After Autonomous Vehicle Swept into Creek
Waymo Voluntary Recall Follows Robotaxi Swept Into Creek Incident
New EDU Crushes Q1 2026 Estimates EPS 095 Tops Views
Post Office Horizon Scandal Inquiry Faces FiveYear Delay Without Extra Funding Police Warn
CLARITY Act Passage Odds Decline as Spain Blocks Prediction Markets Regulatory Uncertainty Looms
Burberry Shares Rally on Report of Potential Moncler Bid
CBS Paramount Retreat from Copyright Enforcement Over Colberts Viral Cable Access Appearance
ConocoPhillips May Offer Portfolio Hedge Amid Market Volatility
ONL Q1 2026 Earnings Significant EPS Miss as Losses Widen
Clover Health Q1 2026 Earnings EPS Surges 12876 Above Estimates Stock Reaction Muted
RMBS Q1 2026 Earnings EPS Misses Estimates Stock Edges Higher Despite Revenue Discrepancy
ERAS Q1 2026 Earnings EPS Misses Estimates by Wide Margin Shares Decline 315
Outset Medical Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Reaction
Nexgen Energy Ltd NXE Climbs 263 as Stock Tests Key Resistance Zone
Better Home Finance BETR Rallies 23 as Investors Eye Key Resistance at 2689
Green Circle Decarbonize Technology GCDT Plunges 10 as Bears Test Critical Support
F5 Inc FFIV Rises 259 Key Levels and Technical Outlook
Yardeni Warns Federal Reserve May Need July Rate Hike to Appease Bond Vigilantes
XFAB Shares Surge on Social Media Buzz Outpacing Infineon in Retail Trading
Idaho Chip Manufacturer Surges to 1 Trillion Market Cap in Record 48Day Run
Amazon Posts Record Thanksgiving Holiday Week Sales
Worthington Steel Inc WS Q1 2026 Earnings Earnings Miss Weighs on Results Stock Edges Higher
FIP Q1 2026 Earnings Significant EPS Miss Weighs on Shares
CRVO Q1 2026 Earnings EPS Miss Reflects Continued Clinical Investment
DRCT Q1 2026 Earnings EPS Beats Estimates Despite Negative Results
HMN Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction
Marker Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Progresses